Journal rankings · indicator year 2025
Choose a field to open its ranking, or a journal to find its row in its subfield’s list.
Subfield ranking · 2025
Cancer Research journal rankings 2025
29 ranked journals · Subfield in Biochemistry, Genetics and Molecular Biology
Cancer Research has 29 ranked journals in 2025. The median journal has an OJR of 0.80, below the world average of 1.00, up 0.03 on 2024; Q1 starts at OJR 1.04. No journal’s likely rank range stays within the top 3, so the intro names none.
Ranks and citation indicators: 2025. Journal access status and listed APC: source snapshot September 23, 2026.
Journals whose main subfield sits in this category and that published at least 30 citable documents (articles, reviews and conference papers) in 2022–2024, the window the 2025 score is computed on.
The OpenJournalRank Indicator (OJR) is a free, publicly available metric of a journal’s field-normalized citation impact, computed from open OpenAlex citation data. It compares citations to a journal’s papers from the previous three years with the world average for papers of the same subfield, year and type, so 1.00 is the world average and values can be compared across fields. It is computed with the NCI3 method.
The middle OJR among ranked journals in this category: half score higher, half lower. 1.00 is the world average for papers of the same subfield, year and type.
The dot is this category, the solid tick is the median of all ranked journals and the dashed line is the world average.
Share of ranked journals in this category that are fully open access, so every paper is free to read. Hybrid journals, which sell subscriptions and open single papers for a fee, are not counted.
Median list price of the article processing charge, in US dollars, among ranked journals in this category that list a price above zero. Journals with a listed APC of $0 and journals with no known price are left out of this median. The At a glance table below gives a second median that includes the $0 prices.
Subfields of Biochemistry, Genetics and Molecular Biology (14)
29 ranked journals
Filters
Rank is the position by OJR within the list on screen; 1 is the highest. The small range under it is the likely rank range: in 95% of 1,000 resamples of the journal’s papers, it ranked inside that range. Journals whose ranges overlap are not clearly different. | OJR is field-normalized 3-year citation impact: 1.00 is the world average for papers of the same subfield, year and type, so values compare across fields. The badge is the journal’s quartile in this list. | Citations per paper over a two-year window, counted from OpenAlex. It is not field-normalized, so compare it only between journals of the same field. ▲ or ▼ is the change from 2024. This is OpenJournalRank’s own count, not Clarivate’s Journal Impact Factor. | Citable documents (articles, reviews and conference papers) published in 2022–2024, the window the 2025 OJR is computed on. A journal needs at least 30 to be ranked. | Share of the journal’s 2022–2024 papers that are free to read in any open-access form. The green OA tag next to a title marks a fully open-access journal. | List price of the article processing charge in US dollars. “$0 listed” means the listed price is zero; a dash means no price is listed. | The line is the journal’s OJR from 2016 to 2025. A label compares the 2022→2025 change with the median change of the journal’s field or domain. Rising needs a relative change of +10% or more that is at least 2 standard errors above zero; Falling needs -9.1% or less (rounded), at least 2 standard errors below zero. Sorting uses that relative change. | Compare |
|---|---|---|---|---|---|---|---|
Rank 1; likely between #1 and #6 of 29British Journal of Biomedical ScienceOATaylor & Francis · United Kingdom | 3.20Q1 | 14.21 8.33 up from 2024 | 85 | 100% | $2,506 | ||
Rank 2; likely between #1 and #6 of 29The BreastOAElsevier BV · United Kingdom | 2.00Q1 | 4.40 3.42 down from 2024 | 471 | 100% | $3,200 | Rising vs field, 2022–25 | |
Rank 3; likely between #1 and #4 of 29Cancer & MetabolismOABioMed Central · United Kingdom | 1.72Q1 | 6.08 0.40 up from 2024 | 90 | 100% | $3,190 | ||
Rank 4; likely between #3 and #7 of 29Non-coding RNA ResearchOAElsevier BV · China | 1.29Q1 | 5.50 0.29 up from 2024 | 260 | 100% | $1,100 | ||
Rank 5; likely between #3 and #11 of 29Mutation Research/Reviews in Mutation ResearchElsevier BV · Netherlands | 1.19Q1 | 6.87 2.33 up from 2024 | 55 | 56% | $4,160 | ||
Rank 6; likely between #4 and #9 of 29Journal of Molecular DiagnosticsElsevier BV · United States | 1.13Q1 | 3.65 0.26 up from 2024 | 320 | 74% | $3,000 | ||
Rank 7; likely between #4 and #15 of 29The Journal of Liquid BiopsyOAElsevier BV | 1.05Q1 | 5.43 2.35 up from 2024 | 69 | 100% | $2,080 | ||
Rank 8; likely between #3 and #19 of 29MutagenesisOxford University Press · United Kingdom | 1.04Q1 | 3.33 1.90 down from 2024 | 85 | 59% | $4,170 | ||
Rank 9; likely between #8 and #13 of 29Breast Cancer Research and TreatmentSpringer Science+Business Media · Netherlands | 0.93Q2 | 3.33 0.18 up from 2024 | 1,083 | 53% | $4,190 | ||
Rank 10; likely between #6 and #15 of 29Breast CancerSpringer Science+Business Media · Japan | 0.91Q2 | 3.63 0.78 up from 2024 | 328 | 47% | $3,890 | ||
Rank 11; likely between #4 and #22 of 29Journal of Breast CancerOASouth Korea | 0.91Q2 | 4.16 1.48 up from 2024 | 133 | 100% | $500 | ||
Rank 12; likely between #8 and #14 of 29Pathology - Research and PracticeElsevier BV · Germany | 0.90Q2 | 3.88 0.40 up from 2024 | 1,707 | 21% | $2,780 | Rising vs field, 2022–25 | |
Rank 13; likely between #7 and #20 of 29Biomarker InsightsOASAGE Publishing · United Kingdom | 0.85Q2 | 2.06 0.89 down from 2024 | 66 | 100% | $2,650 | ||
Rank 14; likely between #8 and #20 of 29BiomedicineOAEDP Sciences · Netherlands | 0.80Q2 | 2.68 0.08 down from 2024 | 83 | 100% | — | ||
Rank 15; likely between #9 and #19 of 29Non-Coding RNAOAMultidisciplinary Digital Publishing Institute · Switzerland | 0.80Q2 | 3.91 0.91 up from 2024 | 217 | 100% | $2,172 | Falling vs field, 2022–25 | |
Rank 16; likely between #8 and #24 of 29Advances in Biomarker Sciences and TechnologyOAElsevier BV · China | 0.69Q3 | 1.97 0.26 down from 2024 | 43 | 100% | $700 | ||
Rank 17; likely between #11 and #23 of 29The Breast JournalOAWiley · United Kingdom | 0.68Q3 | 2.41 0.17 up from 2024 | 106 | 100% | $2,350 | ||
Rank 18; likely between #15 and #21 of 29Clinical Breast CancerElsevier BV · United States | 0.67Q3 | 2.63 0.14 up from 2024 | 509 | 27% | $3,470 | ||
Rank 19; likely between #9 and #24 of 29Journal of Molecular PathologyOAMultidisciplinary Digital Publishing Institute · Switzerland | 0.66Q3 | 2.87 1.54 up from 2024 | 91 | 100% | $1,207 | ||
Rank 20; likely between #15 and #23 of 29Mutation Research/Genetic Toxicology and Environmental MutagenesisElsevier BV · Netherlands | 0.63Q3 | 2.82 0.44 up from 2024 | 209 | 22% | $3,350 | ||
Rank 21; likely between #15 and #23 of 29Environmental and Molecular MutagenesisWiley · United States | 0.62Q3 | 2.62 0.12 up from 2024 | 128 | 63% | $3,750 | ||
Rank 22; likely between #15 and #23 of 29Breast Cancer Basic and Clinical ResearchOASAGE Publishing · United States | 0.61Q3 | 2.30 0.23 up from 2024 | 62 | 100% | $2,650 | ||
Rank 23; likely between #17 and #24 of 29Genes and EnvironmentOABioMed Central · Japan | 0.54Q4 | 2.11 0.08 down from 2024 | 89 | 100% | $2,590 | ||
Rank 24; likely between #23 and #26 of 29MicroRNABentham Science Publishers · Netherlands | 0.38Q4 | 1.60 0.12 up from 2024 | 80 | 16% | — | ||
Rank 25; likely between #23 and #26 of 29Breast DiseaseIOS Press · Netherlands | 0.38Q4 | 1.41 0.40 up from 2024 | 133 | 100% | — | ||
Rank 26; likely between #24 and #26 of 29Critical Reviews in Eukaryotic Gene ExpressionBegell House · United States | 0.36Q4 | 1.21 0.27 down from 2024 | 159 | 0% | — | ||
Rank 27; likely between #27 and #27 of 29Journal of Biomaterials and Tissue EngineeringAmerican Scientific Publishers · United States | 0.05Q4 | 0.30 0.15 up from 2024 | 453 | 100% | — | ||
Rank 28; likely between #28 and #29 of 29International Journal of Human GeneticsOAKamla Raj Enterprises · India | 0.02Q4 | 0.00 0.09 down from 2024 | 46 | — | — | ||
Rank 29; likely between #28 and #29 of 29Breast Global JournalMedknow | 0.01Q4 | 0.06 0.03 up from 2024 | 48 | 100% | — |
2 Cancer Research journals are labelled rising: their OJR moved up between 2022 and 2025 clearly faster than the median journal of their field or domain.
A journal is rising when its OJR grew from 2022 to 2025 faster than the median journal of its field (or domain, when the field is small), by two tests: the relative change is +10% or more, and it is at least 2 standard errors above zero. So the range of the change at 2 standard errors stays above zero, though not necessarily above +10%.
The bar is that range on a ratio scale; the shaded band, -9.1% to +10%, holds changes too small for a label. The list is ordered by the low end of the range, so the surest rises come first.
- 1The BreastOAElsevier BV · United Kingdom+202% vs groupOJR 0.72 → 2.00range +59% to +476%
- 2Pathology - Research and PracticeElsevier BV · Germany+31% vs groupOJR 0.75 → 0.90range +17% to +46%
No-label zone, -9.1% to +10%Group median changeBar scale -84% to +528% (ratio scale)
1 Cancer Research journals are labelled falling: their OJR moved between 2022 and 2025 clearly behind the median journal of their field or domain.
A journal is falling when its OJR changed from 2022 to 2025 by less than the median journal of its field (or domain, when the field is small), by two tests: the relative change is -9.1% or less (rounded), and it is at least 2 standard errors below zero. So the range of the change at 2 standard errors stays below zero, though not necessarily below -9.1%.
The bar is that range on a ratio scale; the shaded band, -9.1% to +10%, holds changes too small for a label. The list is ordered by the high end of the range, so the surest falls come first.
- 1Non-Coding RNAOAMultidisciplinary Digital Publishing Institute · Switzerland-29% vs groupOJR 1.21 → 0.80range -48% to -2.6%
No-label zone, -9.1% to +10%Group median changeBar scale -49% to +97% (ratio scale)
Subfields of Biochemistry, Genetics and Molecular Biology, with Cancer Research highlighted.
- Molecular Biology1,152
- Genetics125
- Cancer Research29
- Cell Biology28
- Molecular Medicine12
- Biophysics10
- Clinical Biochemistry4
- Biochemistry3
- Structural Biology2
- Developmental Biology1
- Physiology1
- Aging0
- Biotechnology0
- Endocrinology0
Journals
The endpoints below each rank show its likely range. How rank ranges are calculated
Citations made in 2025. Corpus-wide, 84.3% of core-journal articles and reviews published that year have at least one matched reference; the share varies by journal and field.
9 additional Cancer Research journals with metrics are unranked under this release’s eligibility rules: a journal needs at least 30 citable documents in 2022–2024, at least 80% of them with a subfield, and a positive world-average expectation. Ranks are within the whole category; filters hide rows without re-ranking. OJR excludes self-citations.
At a glance
Indicator year: 2025. Publication window: 2022–2024. How these summaries are calculated
- Ranked journals
- 29
- Window papers (baseline)
- 56,699 -12.1% from indicator year 2022
- Median OJR
- 0.7966 +13.6% from indicator year 2022
- Rising journals (2025)
- 2
Window papers are the baseline paper population: citable papers (articles, reviews and conference papers) from 2022–2024 in all journals of the world-average baseline, including non-core journals, counted by each paper’s own subfield. They are not the papers of the ranked journals alone.
| Measure | Year series | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ranked journals | 12 | 14 | 15 | 16 | 16 | 19 | 20 | 21 | 21 | 22 | 21 | 20 | 21 | 24 | 23 | 25 | 26 | 27 | 28 | 27 | 29 | 27 | 27 | 26 | 27 | 29 | |
| Window papers (baseline) | 14,247 | 15,312 | 16,615 | 17,745 | 18,774 | 20,529 | 22,718 | 25,259 | 27,535 | 30,135 | 32,914 | 35,940 | 38,839 | 41,424 | 44,722 | 47,640 | 50,019 | 51,182 | 52,328 | 54,530 | 57,576 | 61,698 | 64,508 | 64,646 | 60,806 | 56,699 | |
| Median OJR | 0.49 | 0.50 | 0.46 | 0.60 | 0.71 | 0.58 | 0.67 | 0.680 | 0.768 | 0.8139 | 0.72 | 0.798 | 0.93 | 0.92 | 0.88 | 0.84 | 0.7969 | 0.8143 | 0.804 | 0.82 | 0.76 | 0.679 | 0.70 | 0.79 | 0.770 | 0.7966 |
How to read these rankings
- OJR, the OpenJournalRank Indicator
- A field-normalized 3-year citation impact, computed from OpenAlex with the NCI3 method. It divides the citations a journal’s papers received by the world average for papers of the same subfield, year and type, so 1.00 is the world average and 2.00 means twice as many citations as expected. Because it is normalized, it can be compared across fields. Read the methodology
- Quartiles
- Q1 to Q4 split the ranked journals of the list you are viewing into four equal groups by OJR. A journal’s quartile depends on the list: the same journal can be Q1 in its subfield and Q2 among all journals.
- Impact factor (2-year)
- Citations per paper over a two-year window, counted from OpenAlex. It is easy to compare with familiar impact factors but is not field-normalized, so compare it only within a field. It is not Clarivate’s Journal Impact Factor. Why it differs from the Journal Impact Factor
- Rank ranges
- Each rank in the latest year carries a likely range from 1,000 resamples of the journal’s papers. Where two journals’ ranges overlap, the data cannot tell them apart, so treat neighbouring ranks as ties.